Eclipse 3 + FeLV

Manufacturer: Intervet/Schering-Plough Animal Health

Feline Leukemia-rhinotracheitis-calici-panleukopenia Vaccine

Modified Live And Killed Virus

For veterinary use in cats only

Product Description

Eclipse* 3 + FeLV vaccine is a combination vaccine that unites the benefits of Eclipse* 3 and Fevaxyn* FeLV in one vaccination.

Eclipse 3 vaccine is a modified live virus vaccine for the vaccination of healthy cats as an aid in the prevention of disease caused by feline rhinotracheitis, calici, and panleukopenia viruses.

Fevaxyn FeLV vaccine is recommended for the vaccination of healthy cats as an aid in the prevention of lymphoid tumors caused by, and diseases associated with, feline leukemia virus (FeLV) infection. Vaccination with this product prevents persistent viremia in cats exposed to virulent feline leukemia virus.

Fevaxyn FeLV contains a tissue culture derived feline leukemia virus, Subgroups A and B. The virus has been chemically inactivated and combined with a proprietary adjuvant designed to enhance the immune response.

Eclipse 3 + FeLV Dosage And Administration

Transfer contents of the Fevaxyn FeLV vial to the Eclipse 3 vial aseptically. Mix gently until dissolved. Use entire contents immediately after rehydration.

Prior To Use, Warm The Fevaxyn Felv To Room Temperature And Shake Well.

Two doses are required for primary immunization.

Initial vaccination: Inject 1 dose (1 mL) subcutaneously or intramuscularly at 9 weeks of age or older.

Second vaccination: Inject 1 dose (1 mL) subcutaneously or intramuscularly 3 to 4 weeks following the initial vaccination.

Annual revaccination with one dose is recommended.

Precautions

Store at 2°-7°C.

Do not freeze.

Do not mix with other vaccines.

Use new, non-chemically sterilized needles and syringes.

Burn vaccine container and all unused contents.

Warnings

Contains gentamicin and amphotericin B as preservatives.

Some reports suggest that in cats, the administration of certain veterinary biologicals may induce the development of injection-site fibrosarcomas.

Do not vaccinate pregnant cats.

The use of a biological product may produce anaphylaxis and/or other inflammatory immune-mediated hypersensitivity reactions.

Antidote

Epinephrine, corticosteroids, and antihistamines may all be indicated depending on the nature and severity of the reaction.

It is important to realize that certain conditions and event may cause some cats to be unable to develop or maintain an adequate immune response following FeLV vaccination. Prior exposure to the disease, or disease latency, are conditions in which vaccination may not alter the course of the disease. Therefore, diagnostic testing of all cats for FeLV antigen prior to vaccination is recommended. Also, vaccination with this product will not offer cross-protection against feline immunodeficiency virus (FIV), another feline retrovirus. It is important to advise the cat owner of these situations prior to vaccination.

U.S. Veterinary. Lic. No. 165A

Schering-Plough Animal Health Corporation, Omaha, NE 68103 USA

1 800 224-5318 (USA)

1 888 306-0069 (Canada)

© Copyright 1999, 2001, 2006, Schering-Plough Animal Health Corp.

All rights reserved.

* Reg. U.S. PAT & TM OFFICE Trademark

	NDC
25x1 DOSE	0061-1382-01	P20201-12

Nac No.

10470503